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Despite  a  recommendation  by the  World  Health  Organization  (WHO)  that typhoid  vaccines  be  consid-
ered  for the  control  of  endemic  disease  and  outbreaks,  programmatic  use  remains  limited.  Transmission
models  and  economic  evaluation  may  be  informative  in  decision  making  about  vaccine  programme
introductions  and  their  role  alongside  other  control  measures.  A literature  search  found  few  typhoid
transmission  models  or economic  evaluations  relative  to analyses  of  other  infectious  diseases  of  similar
or lower  health  burden.
Modelling  suggests  vaccines  alone  are  unlikely  to eliminate  endemic  disease  in  the short  to  medium
term  without  measures  to reduce  transmission  from  asymptomatic  carriage.  The  single  identiﬁed
data-ﬁtted  transmission  model  of typhoid  vaccination  suggests  vaccines  can  reduce  disease  burden
substantially  when  introduced  programmatically  but that  indirect  protection  depends  on  the  relative
contribution  of  carriage  to  transmission  in  a  given  setting.  This  is an  important  source  of  epidemiological
uncertainty,  alongside  the extent  and  nature  of natural  immunity.
Economic  evaluations  suggest  that  typhoid  vaccination  can  be  cost-saving  to health  services if incidence
is  extremely  high  and  cost-effective  in other  high-incidence  situations,  when  compared  to  WHO  norms.
Targeting  vaccination  to  the  highest  incidence  age-groups  is  likely  to  improve  cost-effectiveness  sub-
stantially.  Economic  perspective  and  vaccine  costs  substantially  affect  estimates,  with  disease  incidence,
case-fatality  rates,  and  vaccine  efﬁcacy  over  time  also  important  determinants  of cost-effectiveness  and
sources of uncertainty.  Static  economic  models  may  under-estimate  beneﬁts  of typhoid  vaccination  by
omitting  indirect  protection.
Typhoid  fever  transmission  models  currently  require  per-setting  epidemiological  parameterisation  to
inform their  use  in economic  evaluation,  which  may  limit  their  generalisability.  We found  no  economic
evaluation  based  on  transmission  dynamic  modelling,  and no  economic  evaluation  of typhoid  vaccination
against  interventions  such  as improvements  in sanitation  or hygiene.
© 2015  Published  by Elsevier  Ltd.. Introduction
Typhoid fever is an exclusively human enterically transmitted
ystemic disease caused by infection with the bacterium Salmonella
nterica enterica serovar Typhi. Although largely controlled in
urope and North America, typhoid remains endemic in many parts
f the world, notably Asia, where it is an important cause of febrile
llness in crowded, low-income settings [1]. A notable feature of
yphoid is the carrier state – asymptomatically infected individ-
als who continue to shed Salmonella Typhi in their stool or urine
or many years, thereby sustaining transmission [2].
∗ Corresponding author. Tel.: +44 2079588273.
E-mail address: Conall.watson@lshtm.ac.uk (C.H. Watson).
ttp://dx.doi.org/10.1016/j.vaccine.2015.04.013
264-410X/© 2015 Published by Elsevier Ltd.Despite a recommendation by the World Health Organization
in 2008 that typhoid vaccination be considered for the control of
endemic disease and outbreaks, programmatic use remains limited
[3].
In the early twentieth-century, public health ofﬁcials were
debating the best methods of evaluating typhoid vaccine effec-
tiveness, and whether vaccination was  a distraction from
improvements in sanitation and hygiene [4]. These remain con-
temporary policy issues for ministries of health and other health
partners who may  be considering programmatic anti-typhoid vac-
cination as a counterpart to other anti-typhoid measures such
as improvements to income distributions, sanitation, water sup-
plies and hand washing with soap (post-defecation and before the
preparation of food in the home or sold in the street) as well as iden-
tiﬁcation and management of carriage [5–8]. Transmission dynamic
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mally ﬁtted to data [24,25].
The structures of models (Tables 2a and 2b) are based on dif-
ferent assessments or representations of the natural history of
typhoid fever, particularly in how immunity to Salmonella Typhi is
Table 1
Summary of typhoid transmission model types.
Characteristic Number of
models (n = 7)
References
Type of model
Compartmental
Deterministic 6 [18–24]
Stochastic 0
Individual-based stochastic 1 [25]
Scope of model
Analytical/mathematical
Without data 1 [22]
Uses data without ﬁtting 1 [23]
Exploratory/epidemiological
Uses data without ﬁtting 1 [21]
Fitted to data 1 [25]
Policy-oriented/public health
Uses data without ﬁtting 2 [18–20]
Fitted to data 1 [24]
Parameter-ﬁtting method
Maximum likelihood estimation 2 of 2 [24,25]
Bayesian 0
Investigates vaccination 4 [18–21,24]C.H. Watson, W.J. Edmund
odelling and economic evaluation are two informative tools to
upport such decisions [9,10].
Where health budgets are limited, allocation of resources to
ctivities which generate the best value for money maximises the
opulation’s health (not withstanding other health programme
riteria such as equity). To compare between and across health
tates, cost utility analysis (CUA) can be employed using a com-
on  metric of health, such as disability-adjusted life-year (DALY).
he World Health Organization’s Choosing Interventions that are
ost-Effective project (WHO-CHOICE) describes interventions as
cost-effective” if they add a DALY at a cost of less than three
imes Gross Domestic Product (GDP) per capita, and “highly cost-
ffective” if each DALY costs less than GDP per capita. These are
rbitrary thresholds and meeting them does not necessarily lead
o the intervention being adopted, as health decision-makers are
ften required to make choices between multiple interventions
hat fall below these thresholds. Furthermore, even highly cost-
ffective activities may  be too expensive overall for a health service
o provide within budget: a hypothetical drug adding a year of life
nd costing GDP per capita for each person treated would require
he entire national economy to be spent giving the drug to every
ember of the population [11].
By building on the germ theory of disease, and mass-action prin-
iples from the physical sciences [12], mechanistic mathematical
odelling enables extrapolation beyond observed data, and can be
sed to project the expected trends of disease in a population or the
otential impact of control strategies such as vaccination. Through
apturing indirect effects of immunisation – the reduced incidence
f disease in members of a population not themselves immunised,
ommonly described as “herd immunity” – these transmission
ynamic models capture the impact of such interventions more
ompletely than static economic models measuring only the direct
ffects in vaccinees [13].
In this review, typhoid transmission dynamic models and
yphoid vaccine economic evaluations are examined for their
otential contributions to informing disease control, identiﬁca-
ion of gaps in knowledge and indication of directions for further
esearch.
. Methods
PubMed was searched on 23 October 2014 without date restric-
ion using the following terms: (“Typhoid Fever”[Mesh]) AND
“Nonlinear Dynamics”[Mesh] OR “Models, Theoretical”[Mesh] OR
Models, Statistical”[Mesh] OR “Computer Simulation”[Mesh] OR
Models, Economic”[Mesh] OR “Least-Squares Analysis”[Mesh]
R “Likelihood Functions”[Mesh] OR “Resource Allocation”[Mesh]
R “Cost-Beneﬁt Analysis”[Mesh]) AND (Humans[Mesh]) NOT
Mice”[Mesh].
Personal libraries were reviewed and reference lists in papers
earched for modelling and economic studies that may  not
ave been identiﬁed by the above search strategy. Results were
estricted to those available in English. We  obtained information
bout unpublished studies through the Coalition against Typhoid
nd International Vaccine Institute.
Studies were included if they modelled typhoid transmission
nd/or analysed the cost-effectiveness of vaccination in endemic
ettings. Endemic settings were identiﬁed using recent high-quality
eviews [14,15]. We  included cost of illness (COI) studies if they
ere linked to an analytical study, and willingness-to pay (WTP)tudies if they included an economic evaluation or were linked to
n analytical study. Studies were excluded if they used geographi-
al or statistical modelling, including time-series analysis, without
ransmission dynamics, or if they addressed transmission orccine 33 (2015) C42–C54 C43
cost-effectiveness in non-endemic populations, such as interna-
tional travellers.
Transmission models were assessed for their model struc-
ture, data sources, parameter estimates, use of ﬁtting methods,
sensitivity analysis and the contribution of their approach to epi-
demiological understanding of typhoid. Economic studies were
evaluated by data sources, economic evaluation approach, per-
spective, comparator programmes, use of sensitivity analysis and
capture of indirect effects of vaccination.
3. Results
Seventy-nine titles were retrieved. Ten modelling papers were
selected for review based on title or abstract. One was discarded
as a non-mechanistic time series study [16], one as it modelled
outbreaks in a non-endemic setting [17], while two papers were
of the same model and considered together [18,19]. These are
summarised in Tables 1 and 2. A further, as yet unpublished, trans-
mission model has been developed by the International Vaccine
Institute (personal communication, Jin Kyung Park) and is not
reviewed here.
Seven titles were identiﬁed as economic evaluation and
obtained for full-text review (Tables 3 and 4) alongside two  under-
pinning COI studies and one underpinning WTP  study (Table 5). A
further COI study was  identiﬁed but excluded as not linked to a
published economic evaluation [40].
There was minimal overlap found between transmission mod-
elling and economic evaluation. Of the transmission dynamic
models, only those by the Cvjetanovic´ group also had cost-
effectiveness components [18–20]. One economic study included
quantitative consideration of indirect protection [27].
3.1. Transmission dynamic models
The seven typhoid models identiﬁed range from two-state ana-
lytical tools to complex individual-based simulation or multi-state
compartmental models (see Table 1). Only two models were for-Compares with improved sanitation,
hygiene or water supply
4 of 4 [18–21,24]
Include economic evaluation of
vaccination
2 of 4 [18–20]
C
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Table 2a
components and main ﬁndings of typhoid transmission models.
First author
and year
Model type Disease states Data source(s) Fitting process Interventions
modelled
Time horizon Sensitivity analysis Findings Comments
1 Cvjetanovic´
1971, 1978
[18] [19] Compartmental
deterministic
with
births = deaths,
without
age-structure
N  S Es Ea Is Ia Ct
Cl Rt Rl
Parameters
estimated using
literature and
expert opinion.
Considers an
eidemiological
scenario
approximating
Western Samoa.
None Vaccination
with
whole-cell
inactivated
vaccines, VE
60%, 75% or
90%,
coverage 60,
80 or 100%.
As one-off or
5 yearly
campaigns.
Sanitation
60 years Epidemiological/clinical
parameters ﬁxed.
Effective contact
rate (per capita per
day) varied.
For both low and high VE,
single vaccination campaigns
achieve temporary reduction
in incidence rates before return
to  a rate determined by the
force of infection, where force
of infection is above an
elimination threshold.
Sustained reduction in force of
infection reduces incidence.
Multiple vaccination
campaigns reduce incidence
will campaigns are sustained.
Multiple parameters
are included without
ﬁtting.
Outputs should be
considered illustrative.
2  Briscoe
1980
[22] Deterministic
analytical SIS
S I N/A N/A. Reviews
Cvjetanovic´
models.
Analysis of role
of force of
infection and
recovery on
equilibrium
prevalence.
N/A N/A N/A Force of infection determines
prevalence, and vice versa.
Stochasticity may prevent
disease eradication.
Intended as an
analytical model rather
than epidemiological
simulation.
3  Bailey 1982 [23] Compartmental
deterministic
with
births = deaths,
without
age-structure
S  E I C R [18] Rule-based
simpliﬁcation
of Cvjetanovic´
1971 model
[18] with direct
mathematical
solution of
steady-state
equations.
N/A N/A N/A, suggests an
approach to
sensitivity analysis
[26]
For a steady-state model,
structural simpliﬁcation results
in compartment population
estimates consistent with the
unsimpliﬁed model for a given
effective contact rate.
Reducing the number
of compartments
makes a model more
suitable for validation
with data.
4  Cvjetanovic´
1986
[20] Age-structured
compartmental
deterministic
SIRS.
Birth and death
rates from
Chile
N S I Ct Cl Rt Rl Demographic and
typhoid
surveillance data
for Santiago and
rest of Chile
Effective
contact rate
per capita per
unit day
(age-speciﬁc
for acquisition)
from linear
interpolation of
age-speciﬁc
incidence.
Visual
goodness-of-
ﬁt.
Strong
assumption
that 20% of all
cases are
clinical.
Vaccination
with Ty21a,
95% VE at
75% or 95%
coverage of
under 25s
with 5 yrly
revaccina-
tion. Food
sanitation in
schools
reducing
force of
infection by
1/3 in ages 6
to 16 y.
Sanitation
with annual
2% or 5%
improvement
in force of
infection
over 10 years.
Interventions
analysed
over 25 y
after run-in
to
equilibrium.
None Vaccination campaigns would
reduce age-speciﬁc incidence
and increase the age of peak
incidence
Vaccination would not
eliminate disease over 25 y but
would result in year on year
reduction in incidence if
sustained.
10  y sanitation campaigns
likely to reduce prevalence and
continue to reduce prevalence
after cessation.
Somewhat simpliﬁed
model structure,
though now age
structured. The model
is not validated
sufﬁciently against
data, nor are outputs
sufﬁciently clear to
make strong policy
conclusions.
Age-based changes in
incidence with
vaccination are
consistent with
epidemic theory.
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5 González-
Guzmán
1989
[21] Compartmental
deterministic
SIS structure
with births and
deaths
S I V with
environmental
transmission
Parameter
estimates for Chile
None,
analytical
model
Reductions in
combinations
of:
carrier
prevalence
indirect
contact rate
direct contact
rate
environmen-
tal life of the
bacterium
bacterial
count in the
environment.
Vaccination
with Ty21a,
coverage
scaled for
equivalence
to VE 74% or
95%.
10 y N/A Decline in incidence is not
rapid, even with highly
effective combined control
measures.
Reduction in chronic carriage
most effective control
procedure.
Vaccination as a permanent
programme would require a
high proportion of the
population to become immune
to control typhoid within a
meaningful timeframe.
Author cautions
against using the
model to estimate the
effect of a vaccination
programme but that it
indicates areas for
further epidemiological
parameter
determination.
6  Saul 2013 [25] Individual-
based
stochastic,
random-
mixing.
S E Is Ia Ct Cl Rt
Rl, Rc,;Rs; Vc Vs
Surveillance data
from Dhaka,
Bangladesh, and
Kolkata India.
Migration, birth
and death rates
from Matlab,
Bangladesh.
Other parameter
from literature and
expert opinion.
Maximum
likelihood and
visual
inspection
None 40 y to
equilibrium
and 40 y
follow-up. 20
y for effects
of carriage.
Sensitivity analysis
on refractory
period from birth.
Distinguishes between sterile
immunity and clinical
Immunity (in which
individuals can be infected but
not develop disease). Multiple
infections needed to develop
sterile immunity.
Natural immunity is likely to
be long-lasting but needs
further ﬁeld investigation.
Carriage stabilises dynamics,
and is particularly important in
lower incidence settings.
Complex agent based
model, limited
availability of
epidemiological data
results in issues of
parameter
identiﬁability.
Plausible combinations
of parameters
identiﬁed.
C
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Table 2a (Continued)
First author
and year
Model type Disease states Data source(s) Fitting process Interventions
modelled
Time horizon Sensitivity analysis Findings Comments
7 Pitzer 2014 [24] Compartmental,
age-structured
deterministic
S1 S2 I1 I2 R C W Surveillance case
series, Vellore,
Tamil Nadu, India
Two-stage
ﬁtting with
Latin
hypercube
sampling of
starting
parameters.
Maximum
likelihood
estimation,
simplex
method.
Vaccination
with:
Ty21a, (VE
48%, dura-
tion = natural
immunity),
Vi polysac-
charide (VE
80%, 3 y), Vi
conjugate
(VE 95.6%,
19.2 y).
Vaccination
of school age
children as a
campaign,
routine
vaccination
of 6 year
olds, or both
together.
Improvements
in water and
sanitation
over 30 y
50 y to
quasi-steady
state and 25
y  follow-up
Multi-parameter
sensitivity analysis
in model ﬁtting.
Basic reproduction number is
around 3 in Vellore and 7 in
Dhaka.
Natural immunity is likely to
be long-lasting.
Vaccination campaigns would
not eliminate disease in Vellore
but instead see disease
rebound in 5 to 10 y.
A campaign plus routine
immunisation could result in a
new lower incidence disease
state.
High baseline carriage rates
reduce the indirect protection
of vaccines–understanding
carriage prevalence should be a
disease control priority.
In most circumstances
modelled, improvements in
hygiene and sanitation have
more impact than vaccination.
Best ﬁtting parameter
sets were highly
sensitive to initial
parameter selection.
Identiﬁes carrier
transmissibility and
relative contributions
of short- and long-
cycle as import
epidemiological
sources of uncertainty.
VE = vaccine efﬁcacy. Effective contact rate is the rate at which two individuals come into contact per unit time, with the nature of the contact being such that if one was  infectious and the other susceptible, infection would be
transmitted.
C.H. Watson, W.J. Edmunds / Vaccine 33 (2015) C42–C54 C47
Table  2b
Disease states in typhoid models.
Abbeviation Disease state Comment
N Newborn Susceptible in Cvjetanovic´’s model, refractory in Saul’s
S  Susceptible;
S1 S2 Fully and partially susceptible
E; ‘Exposed’; Infected but not (yet) infectious
Es; Ea Symptomatic or asymptomatic
I;  Infectious;
Is Ia Symptomatic or asymptomatic Primary infection of a fully susceptible individual or asymptomatic/subclinical infection of
a  previously partially susceptible individualI1 I2 Primary or subclinical infection
C; Carrier;
Ct; Cl Temporary; long-term
R;  Removed/resistant/refractory/recovered; Not able to be infected, immune.
Rt; Rl; Temporary immunity; long-term immunity; Clinical immunity is against disease but allows infection and onward transmission.
Rc; Rs Natural immunity to clinical disease; natural
sterile immunity)
Sterile immunity is against any infection.
V  Vaccinated
Vc; Vs Vaccine-induced immunity to clinical
disease; Vaccine-induced sterile immunity
W ‘Water’ Long-cycle transmission from water or environmental contamination, contributed to by
all  infectio
Table 3
Summary of typhoid vaccine economic evaluation types.
Characteristic Number of studies
(n = 7)
Reference
Based on ﬁeld studies 5 [27–31]
Perspective:
Public sector only 2 [27,32]
Private only 1 [29]
Societal (public and private) 4 [28–31,33]
Include intangible costs of pain,
suffering and disability
3 [28,30]
Analytical approach: (a study can include more than one approach)
Cost-beneﬁt analysis component 4 [29–32]
Cost-effectiveness analysis
component
2 [27,32]
Cost-utility analysis component 2 [30,33]
Willingness-to-pay component 4 [27–29]
Price-optimisation model 1 [27]
Include indirect protection of vaccines 1 [27]
Include transmission dynamics 0
Evaluates improve sanitation, hygiene
or water supply as an alternative to or
0
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role of short-cycle and long-cycle (environmental) transmission
[21,24,25].adjunct to vaccination
onsidered. González-Guzmán suggests that natural partial immu-
ity is likely to arise but simpliﬁes to a model with vaccine immu-
ity only, noting that sufﬁciently high infectious doses can over-
ome immunity [21]. Pitzer uses population compartments to sepa-
ately represent immunity against typhoid infection (‘sterile immu-
ity’), and immunity against typhoid disease (‘clinical immunity’),
llowing transition from the latter to either full susceptibility or to a
ubclinical infection that in turn restores full sterile immunity in the
ndividual. This corresponds to immunity boosting repeated infec-
ion cycles without overt disease, particularly in adults after recov-
ry from clinical disease in childhood, and allows bacterial shedding
uring subclinical infection to contribute to sustained transmission
24]. Saul similarly models both sterile and clinical immunity, with
nfection resulting in sterile immunity that wanes to clinical immu-
ity (potentially after zero time) and then to susceptibility, and
xplores a range of hypothetical state-transition scenarios based on
ultiple infections, though he does not clearly resolve a most-likely
cenario [25]. Despite asymptomatic boosting being a long-
tanding hypothesis, or perhaps because of it, there is a paucity
f data from microbiological, immunological or epidemiological
tudies to parameterise models or to validate assumptions [41].us or carrier classes.
While noting leaky immunity in those naturally infected (each
individual has a reduced probability of further infection), González-
Guzmán models Ty21a oral vaccine protection as all-or-none,
giving each vaccinee a probability of developing immunity or not.
In this model, those who develop immunity following vaccination
have 100% protection against typhoid, until vaccine wanes and they
return to full susceptibility, an approach also applied by Cvjetanovic´
[18–21]. Pitzer handles injected Vi vaccination the same, noting
results were similar in a sensitivity analysis assuming leaky vaccine
immunity. Pitzer represents oral Ty21a vaccination as akin to nat-
ural immunity, transitioning vaccinees to clinical immunity after
full immunity wanes [24].
While vaccination programmes are predicted to reduce typhoid
incidence, uncertainty around carriage prevalence, duration and
contribution to the force of infection substantially affects vaccines’
projected impact [21,24,25]. In reviewing Cvjetanovic´’s 1978 model
[19], Anderson and May  observe that the implicit assumption that
the effective contact rate for carriers is equal to that of acute
cases, combined with other ﬁxed parameter estimates, gives car-
riers a contribution to transmission ten times that of other cases
[42]. While illustrative of the potential contribution of carriage
in sustaining disease, for policymaking it has been recommended
that such assumptions should be tested against data [43,44]. An
approach might be to conduct systematic, detailed investigation
of incidence cases to identify potential sources, using suitable
screening methods to look for carriers as well as acute cases, and
combine this with population-level carriage surveys and water
quality studies. While labour-intensive, such investigations could
be integrated into wider control efforts [45].
Chronic Salmonella Typhi carriage can be treated with antibi-
otics and/or cholecystectomy for gallstone-associated infection,
but there is no demonstrated role for vaccination in clearance of
carriage [46,47]. Premised on this, Cvjetanovic´’s and Pitzer’s mod-
els demonstrate that where carriage contributes substantially to
transmission in endemic settings, vaccination is unlikely to result in
elimination in the short-to-medium term [18,24]. Similarly, where
carriage rates are high the indirect protective effects of vaccination
are reduced, as the risk to the unvaccinated of acquiring disease
from carriers is not diminished [24,42]. The contribution of carriage,
however, requires further epidemiological assessment, as does theIf immunisation of the susceptible population does not bring
about typhoid elimination, then measures to reduce per case or
C48 C.H. Watson, W.J. Edmunds / Vaccine 33 (2015) C42–C54
Table 4
Components and main ﬁndings of typhoid vaccine economic evaluations.
First author,
year, reference
Analytical
approach
Economic
perspective
Setting Burden of
disease
Costs Vaccine
intervention
modelled
Vaccine
effectiveness
1 Musgrove 1992
[32]
CBA
CEA
Public sector PAHO SIREVA
countries
150 cases per
year per 100k
population.
CFR1%
Does not cost
pain, suffering
or death.
Vaccine
programs and
clinical/ﬁeld
trials or pilots.
Mass
vaccination;
reducing
number of
doses over
time.
Estimated 90%
2  Shepard 1995
[33]
CUA, cost per
QALY
Public sector
costs; societal
beneﬁt
captured as
QALYs
Countries with
middle, high or
very high
U5MR
1.5 cases per
person per
lifetime.
CFR 1.8%
Morbidity is
excluded from
QALY estimates
Marginal costs
of additional
vaccination
within a
childhood
programme
By birth cohort,
two doses
Anticipated
80% over 10 y
3  Poulos 2004
[31]
CBA Multi-
dimensional
public sector
and societal
Kalkaji slum,
New Delhi,
India
As per [35].
Does not cost
pain, suffering
or death.
As above.
Public funded
vaccine
programme.
Campaign with
80% coverage
of:
age 2–5, age
6–19, or
all-age.
70% for 3 years
4  Canh 2006 [29] WTP,
contingent
valuation, CBA
Private Hue, Vietnam Raised
incidence
1995–9;
associated with
outbreak in
1996
Beneﬁts
measured by
WTP.
Proposed USD
0.67
1.70
3.30
6.70
13.30
N/A Proposed:
70%, 3 y;
70%, 20 y;
99%, 3 y;
99%, 20 y
5  Cook 2008 [30] CUA Public sector
and societal
Kolkata, India;
Karachi,
Pakistan; North
Jakarta,
Indonesia; Hue,
Vietnam
Highest in the
sites within
Karachi and
Kolkata, lowest
in Hue.
Reported
incidence
double to
account for
false negative
blood cultures.
DALY weight
0.27, illness
duration 7d
CFR 1%.
Private direct
and indirect
cost of illness
obtained in
interviews
with conﬁrmed
cases, public
costs obtained
from health
facilities.
Public and
private
vaccination
costs from
literature and
estimation.
Campaigns:
1.  School
children 5 to 14
y
2. Children
aged 2–15 y
All 2 y+
65%, 3 y
6  Cook 2009 [28] CBA total
economic
beneﬁts vs
costs
1. Societal COI
2.
Above + Value
of statistical
life (VSL) saved
3. WTP
(contingent
valua-
tion) + public
costs
Societal Tiljala and
Narkeldanga
slums, Kolkata,
India
3.4 case per
1000 2–4 y
4.9 per 1000
5–15 y
1.2 per 1000 16
y+
DALY weight
0.27
CFR 1%
Total marginal
vaccine cost
USD (2007)
$1.11
WTP  as per [36]
VSL from
literature.
Campaigns:
1. School
children 5–14 y
2. Children
aged 2–15 y
All 2 y+
65%, 3 y
7  Lauria 2009
[27]
Optimisation
model:
different adult
and child
pricing,
implicit CEA
Public sector Hypothetical
population
3.5 annual
cases per 1000
children and 1
per 1000 adults
As per [38] Price-
dependent
uptake
70%, 3 y
C.H. Watson, W.J. Edmunds / Vaccine 33 (2015) C42–C54 C49
Table  4 (Continued)
First author,
year, reference
Time horizon Discounting Disease dynamics Sensitivity analysis Data source(s) Findings
1 Musgrove 1992
[32]
14 and 24 years 10% pa No Program
administration costs,
vaccine costs, delay
between accrual of
costs and beneﬁts
Expert opinion Describes incidence,
treatment costs and
vaccination costs at
which a program
would be cost-neutral
2  Shepard 1995
[33]
10 years 3%, costs and
beneﬁts
No. Steady states
pre-and post- vaccine
program start. Assumes
disease most common
in late childhood or
early adulthood.
1. Dose cost at
USD50/QALY.
2. Vaccine
development costs.
Expert opinion;
extrapolation of high
incidence
epidemiological
studies [34]
Preliminary estimate of
highly CE (<USD50 per
QALY, 1992 price) if
data assumptions are
valid.
Critical parameters are
incidence, CFR, VE,
vaccine costs
3  Poulos 2004
[31]
3 years 10% No Incidence; vaccine
cost; ratio of total
economic beneﬁt to
measured COI
Bahl 2004 [35] Immunisation of 2-5
year olds is cost saving
to the public sector in a
high incidence setting.
Sensitivity analysis and
inclusion of private
costs suggest
vaccination of other
ages may  also be highly
CE.
4  Canh 2006 [29] N/A Inherent Typhoid perceived to
be in decline by 67% of
participants
N/A Cross sectional survey
in 2002 of households
with children
Survey participants are
more sensitive to price
than to expected
vaccine efﬁcacy or
duration of protection.
Modest user fees could
support a vaccination
programme.
5  Cook 2008 [30] Over duration
of vaccine
3% No Single parameters and
Monte Carlo across all
parameters, triangular
distribution.
VE 55% to 75%,
duration 2–4 y,vaccine
cost USD 0.40–0.80
(2007 prices), delivery
cost variable.
CFR 0.5–3%, illness
duration 4 d to 3w,
DALY weight
0.08–0.47.
DOMI No programmes would
be cost saving but
(school-) child
immunisation would
be very CE to health
services or society in
all but Hue, including
under sensitivity
analysis.
Adult vaccination in
Kolkata and N. Jakarta
is less CE but still meet
thresholds.
Surveillance likely
reduced illness costs
through early
diagnosis.
6  Cook 2009 [28] 1 year cost, 3
year beneﬁts
3% No As per [30].
VSL varied by 50%
Kolkata [37] Economic perspective
1 is not cost neutral,
but perspectives 2 and
3 indicate beneﬁts
greater than cost across
all campaign strategies.
Sensitivity analyses
suggest WTP  and VSL
models show net
beneﬁt for all campaign
strategies across most
parameter sets.
7  Lauria 2009
[27]
3 y 8% Possible herd
protection described in
a  sensitivity analysis,
with variable adult and
child transmissibility.
Monte Carlo
simulation, allowing
most parameters to
vary.
Five Asian countries
[37]
There is minimal
advantage to different
vaccination charges for
children and adults
under the static model.
Herd protection greatly
inﬂuences case
numbers and value.
CBA, cost-beneﬁt analysis; CE, cost-effective(ness); CEA, cost-effectiveness analysis; CFR, case-fatality rate (proportion of cases that result in death); CUA, cost-utility analysis;
COI,  cost of illness; DALY, Disability adjusted life-year; DALY weight, a scale from 0 (perfect health) to 1 (death). DOMI, Diseases of the most impoverished programme [39];
PAHO,  Pan-American Health Organization; SIREVA, Sistema Regional de Vacunas (Regional Vaccine System); U5MR, under-ﬁve mortality rate; USD, United States Dollars;
VE,  vaccine effectiveness; WTP, willingness to pay.
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Table 5
Components and main ﬁndings of cost of illness studies and willingness to pay studies used in typhoid vaccine economic evaluations.
First author,
year, reference
Analytical
approach
Economic
perspective
Setting Burden of disease Costs Vaccine
intervention
modelled
Vaccine
effectiveness
1 Bahl 2004 [35] Cost of
illness
Multidimensional
public sector
and societal
costs
Kalkaji slum,
New Delhi,
India
Culture conﬁrmed
incidence per year: 17
per 1000 under 5s;
12 per 1000 5–18 y;
1 per 1000 >19 y
Public
sector/institutional
and private costs,
comprising direct
medical, direct
non-medical and
indirect costs; for
hospitalised and
non-hospitalised
N/A N/A
2  Poulos 2011
[38]
COI Public and
private (direct
and indirect)
Hechi, China;
North Jakarta,
Indonesia;
Kolkata, India;
Karachi,
Pakistan; Hue,
Vietnam.
Highest in the sites
within Karachi and
Kolkata, lowest in
Hechi and Hue.
Measured by
questionnaire, with
estimates for
nonmarket activities.
Karachi costs from
expert information.
N/A N/A
3  Whittington
2009 [36]
WTP  Private Tiljala slum
and Beliaghata
neighbour-
hood, Kolkata,
Inida
2 case per 1000
population per year,
peak incidence in older
children and teenagers
Proposed USD (2007)
0.22
0.56
1.11
11.11
And sliding scale.
Price-
dependent
uptake
70%, 3 y
First  author,
year, reference
Time horizon Discounting Disease dynamics Sensitivity
analysis
Data source(s) Findings
1 Bahl 2004 [35] One year
surveillance
N/A No.
Decline in
incidence rate with
age is informative
of an immunising
infection.
With both most
conservative and
least conservative
cost estimates, and
with incidence
both on conﬁrmed
and clinically
suspected disease.
Cohort study
1995–6, weekly
interviews and
passive
surveillance.
Costs are high per episode regardless
of age, both private and
public/institutional. Hospitalisation
and non-response to antimicrobials
increase costs
2  Poulos 2011
[38]
N/A Interviews at
7, 14 and 90 d from
disease onset.
N/A N/A N/A Interviews with
cases or carers.
Total episode costs range from USD
15–132. Private costs exceed public
costs unless reimbursed.
Hospitalisation adds to costs
substantially. 14 to 49% of households
borrowed money to pay for treatment.
Costs of drug resistant infection are
higher, but not signiﬁcantly so.
3  Whittington
2009 [36]
N/A Inherent N/A N/A Cross sectional
survey of
households with
children.
9% would decline a vaccine, with a
further 7% only accepting free vaccine.
WTP  is at least USD2. Vaccines for
children were valued higher than those
for adults.
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wer carrier infectivity, such as improved sanitation or hand washing
ith soap, might be considered instead of or in conjunction with
accination [48,49]. The multi-compartment models suggest such
 reduction in effective contact rates could lead to important reduc-
ion in prevalence [21,23,24]. This is consistent with Briscoe’s
nalytical model [22].
Another feature of transmission dynamic studies is that the
verage age of infection increases as the force of infection decreases,
or example, with the introduction of vaccine [20]. This is consis-
ent with burden of disease studies which ﬁnd earlier average age
f infection in settings with higher disease incidence [14,35].
.2. Economic evaluation
Our literature search found seven papers evaluating typhoid
accine cost effectiveness. The earliest two of which were based
n values derived from expert opinion and are less informative
o current policy considerations than the most recent ﬁve which
ere based on ﬁeld studies, as outlined in Tables 3 and 4. TwoTime to think reduces willingness to
purchase vaccine.
supporting COI studies and one supporting WTP  study are outlined
in Table 5. These ﬁeld-informed analyses share multiple com-
mon  authorships with collaboration through the Diseases of the
Most Impoverished (DOMI) programme. Of the seven economic
evaluations, four included a cost-beneﬁt analysis (CBA), two a
cost-effectiveness analysis (CEA) and two  a cost-utility analysis
(CUA). Four of these used a societal perspective [28,30,31,33].
Only one evaluation considers indirect protection quantitatively,
but uses hypothetical values for herd immunity from different
coverage levels rather than estimates from dynamical modelling
[27]. No studies considered improvements in sanitation, hygiene
or water supply as an alternative or adjunct to typhoid vaccination.
In a one-year study of a very-high typhoid incidence area –
Kalkaji slum, Delhi – Bahl found average costs per episode of ill-
ness were high to both the health sector and families, excluding
intangible costs such as pain, with hospitalisation an important
component of health service costs [35]. A CBA by Poulos on this
data reported that a vaccination programme for children under ﬁve
years of age would be cost-saving to the public sector. Analysis
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rom a societal perspective, incorporating private costs, indicated
hat vaccination in high incidence settings with modestly priced
accines could also have net beneﬁts in other age groups [31].
Cook and colleagues conducted a CUA based on ﬁeld data from
ultiple Asian sites [30,38], and found that while typhoid vac-
ination using the Vi-polysaccharide across adults and children
ould be unlikely to be cost saving to the public sector, in high
ncidence settings it was likely such a programme would meet
he standard for “very cost-effective” health interventions of less
han per-capita gross domestic product (GDP) per DALY gained.
n these settings, targeting vaccination to the highest incidence
ge-groups improved cost-effectiveness substantially. Through
ensitivity analysis, the main determinants of cost-effectiveness
dentiﬁed were vaccine cost, case-fatality rates (CFR), vaccine
uration of protection, (baseline) incidence and vaccine efﬁcacy.
ost-effectiveness was insensitive to vaccine coverage as no indi-
ect protection was assumed [30].
WTP  has also been used in economic evaluation of typhoid vac-
ines as an alternative approach to COI in valuing private or societal
eneﬁts. Such an approach is considered to demonstrate the value
ndividuals place on the total beneﬁt of the vaccine, though is con-
ounded by ability to pay, and ability to value public sector activities
oregone if vaccines are supplied through the state [50]. One study
rom Hue, Vietnam suggested that typhoid vaccination would pass
 social cost-beneﬁt test (total costs less than total societal bene-
t), based on demand estimates from a contingent valuation survey
ddressing hypothetical vaccine purchases for householders and
heir children [29]. Analysis by Cook of a similar WTP  study done in
olkata, India, by Whittington and colleagues, suggested that vac-
ination of children or all-ages would not pass a social cost-beneﬁt
est using COI, but costing beneﬁts using WTP  plus public costs
ould likely ﬁnd that such programmes pass such a test [28,36].
WTP  studies are also informative to vaccine uptake, with 9% of
espondents in the Kolkata survey stating they would not accept
 free vaccine, with data suggesting these individuals are more
ikely to be older, have lower income and never boil drinking water
36]. In the Hue survey, Canh suggests a number of issues affect
alidity of economic evaluation using WTP  estimates, noting that
ouseholders were most sensitive to price, with proposed vaccine
fﬁcacy making no detectable difference to individual or household
emand at a given price [29].
Observing that typhoid vaccines are equivalent to one-sixth of
er-capita public sector health spending in India, Cook notes the
otential for user fees in ﬁnancing a state-administered programme
28]. Whittington’s Kolkata WTP  survey suggested vaccine protec-
ion for children was given greater value than vaccinating adults
36]. Drawing on data from this study, a price optimisation model
y Lauria of different vaccine prices for children and adults did not
nd a strong case for differential pricing, but in a non-dynamic
ensitivity analysis of potential indirect protection scenarios found
erd immunity to be a signiﬁcant inﬂuence on incidence and cost-
ffectiveness [27].
. Discussion
This review found a relatively sparse literature on typhoid mod-
lling and vaccine economic evaluations. Of seven transmission
odels found, only two were published in the last 25 years and
se contemporary data-ﬁtting methods. All ﬁve ﬁeld-based eco-
omic evaluations we found shared multiple common authorships
round the DOMI collaboration.Although the Global Burden of Disease is a much-criticised
anking, it provides some comparator infectious diseases, with
easles and syphilis ranked close to typhoid and paratyphoid
ever, and cholera attributed around one-third of the annualccine 33 (2015) C42–C54 C51
number of DALYs [51]. Repeating our (non-comprehensive)
PubMed typhoid search strategy for these returned over six times
as many measles papers, three times as many syphilis papers, and
twice as many cholera papers. Typhoid fever transmission and
economic evaluation appear relatively under-studied. Typhoid’s
low proﬁle-to-burden ratio has variously been attributed to
ubiquity in developing countries, inadequate diagnostic tools, the
absence of champions in health agencies, and affecting mostly the
poor and the underclasses [52]. Effective antibiotics and previous
non-availability of a long-acting infant vaccine have also been
cited as reasons for the absence of internationally funded typhoid
vaccination programmes [52]. For budget-constrained national
health agencies, typhoid vaccination programmes may  appear
unattractive unless public sector cost saving can be demonstrated,
for example, if the incidence rate is very high [31,35].
Considering only a health services perspective – of treating
typhoid and providing vaccine – omits private costs associated
with the disease and therefore underestimates the societal impact
of typhoid. Various approaches have been taken to address these
costs and more completely capture the beneﬁt of vaccination, from
cost of illness studies for private expenses, estimates of health util-
ity forgone due to illness, or by determining the extent to which
people value vaccination in willingness-to-pay studies. While user
fees and WTP  are controversial [10,50], economic evaluations that
consider these have been consistent with typhoid economic anal-
ysis using more widely accepted cost-utility analysis and private
cost of illness. These CUAs suggest typhoid vaccine programmes
are likely to be highly cost-effective (against international norms)
where disease is highly endemic, particularly when targeted to
the age-groups at highest risk of disease. The economic analyses,
which do not include mechanistic components for transmission,
emphasise as key drivers of cost-effectiveness the vaccine cost, case
fatality rates, baseline incidence, vaccine efﬁcacy and duration of
protection.
We did not ﬁnd any economic evaluation comparing typhoid
vaccination programmes against other potential means of typhoid
control, such as measures to improve sanitation, hygiene or water
supplies. It is still not possible to answer the century-old question
of whether, in a given setting and within a limited budget, vacci-
nation should be adopted over improved sanitation and hygiene,
or what combinations are optimal for control under what circum-
stances. Such analysis would need to be based on a transmission
dynamic model, with extensive epidemiological surveillance for
detailed burden of illness measurement, and comprehensive cost-
ing for CUA or CBA approaches that allow other diseases to be
included in the evaluation.
The only published data-ﬁtted transmission model of typhoid
vaccination suggests that while vaccination is effective in reduc-
ing disease incidence, if other measures are not enacted to reduce
the ongoing force of infection, particularly from asymptomatic car-
riage, short or medium-term vaccination campaigns are unlikely
to result in elimination and would see disease rebound if vaccina-
tion stopped [24]. The authors of recent dynamic models emphasise
our lack of understanding of certain aspects of the natural history
of typhoid (particularly around acquisition of immunity, the role
of carriers, and the contribution of short- and long-transmission
cycles) [21,24,25]. A model intended to examine what role the
putative different forms of Salmonella Typhi immunity have in
determining typhoid incidence rates found an absence of suitable
immuno-epidemiological data on which to ﬁt parameters and make
strong inferences, a challenge further compounded by the absence
of age structure in the model [25].Transmission dynamic modelling and a non-mechanistic eco-
nomic analysis have shown that the level of indirect protection
may  have an important impact on vaccine effectiveness and
cost-effectiveness respectively [24,27]. None of the economic
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odels mechanistically consider disease dynamics and so cannot
cientiﬁcally appraise the indirect effects of vaccination in cost-
ffectiveness calculations. Indeed, while a number of economic
nalyses readily acknowledged indirect effects as an important
henomenon, they speciﬁcally excluded them, citing the absence of
vidence for Vi polysaccharide vaccine herd immunity pending the
ublication of cluster randomised controlled trials [28,30,53,54].
arly work by Cvjetanovic´ is the only meeting point we found
f mechanistic typhoid transmission modelling and economic
nalysis, but the complexity of this model and absence of ﬁtting
ake it difﬁcult to apply ﬁndings to contemporary disease control
roblems [18,19].
Using a static economic model premised only on direct pro-
ection in vaccinees may  be a reasonable approximation in some
ituations, such as if vaccine-preventable new typhoid cases (symp-
omatic or otherwise) make a relatively small contribution to the
orce of infection compared with carriers and the unimmunised.
ven in such circumstances, prior assessment with mechanistic
odelling of ﬁeld epidemiological data would be appropriate in
stimating the relative contributions of each group to transmis-
ion.
While there seems limited inter-disciplinary dialogue between
yphoid modellers and economists, a unifying concern is the
mportance of accurately determining age-based incidence rates,
hich can be highly variable within-country or between other-
ise similar settings, and are central to estimates of vaccine impact
nd cost-effectiveness. Heterogeneity in disease rates, transmis-
ion mechanisms and health service provision may  limit external
alidity of both typhoid modelling studies and economic evalua-
ions.
Accurate assessment of disease burden could be done with
arge, population-based studies to inform incidence, complica-
ions and case-fatality rates, using blood culture conﬁrmation of
ases, or altogether improved diagnostics [30,55–57]. It should be
oted that even well-conducted studies are unlikely to provide
nbiased estimates, due to the positive health consequences of
ntroducing disease surveillance. Bahl notes that active surveil-
ance with early treatment gave rise to disease that is less severe,
nd less expensive, than disease detected through passive surveil-
ance [35]. This is echoed in the DOMI disease burden study,
hich rather than the 1% case-fatality rate widely cited in liter-
ture, had a zero percent CFR amongst the 475 cases detected
which gives an upper 95% conﬁdence interval of around 0.63%)
30,37,58].
Other ﬁeld epidemiology and laboratory investigations could
urther inform typhoid transmission dynamics [59]:
Large, population-based, Salmonella Typhi carriage studies, sim-
ilar to those done in Chile in the early 1980s [5], to determine
prevalence in a range of endemic settings, potentially with sero-
logical surveys [60], alongside investigation of potential sources
of infection amongst new cases.
Serological assay development and population-based serological
surveys to determine past infection to Salmonella Typhi, natural
immunity and waning of this immunity. Seroprevalence could
be linked to surveillance records to estimate the proportion of
infections that are clinically apparent and notiﬁed to national
authorities.
Epidemiological time series with consistent, transparent
methodology and/or cross-referencing between methods [61].
Age-based social contact pattern surveys, which may  inform
short-cycle transmission [62].For models to assess vaccination against other enteric fever con-
rol measures, ﬁndings could be incorporated from interventional
eld studies on the role of improvements to sanitation, hygieneccine 33 (2015) C42–C54
and water supply in changing disease incidence and transmission.
Ongoing scrutiny of vaccine efﬁcacy and duration of vaccine pro-
tection may  also be informative. Estimates of efﬁcacy of Ty21a
vaccines in recent systematic reviews are less than in the data
sources for early modelling, with the reviews focusing on individual
RCTs rather than cluster ﬁeld studies [20,63–66]. Estimates for Vi-
polysaccharide effectiveness have also been modiﬁed downward
[31,64]. Analysis of differences between cluster and individual ran-
domised trials may  be informative on indirect protection.
This review has a number of limitations. In the absence of
licensed human vaccines, the review does not cover paratyphoid
fever or non-typhoidal salmonelloses. It covers only material in the
English language, limited searches to a non-systematic enquiry of
a single database and does not attempt to synthesis qualitatively
or quantitatively any of the studies reviewed. Comparator studies
have not been sought that consider investments in water, sanitation
and hygiene as alternatives to typhoid vaccination.
One possible feature observed in the course of this review is
a less pessimistic assessment of disease burden, perhaps reﬂecting
true decline, as well as a more sceptical perspective on vaccine efﬁ-
cacy estimates, with fewer inputs based on expert opinion alone.
Any such trend towards assessment of vaccine costs and bene-
ﬁt ﬁrmly grounded in data is beneﬁcial to equitable, scientiﬁcally
informed health-policy setting.
It has been suggested that for a model to have sufﬁcient com-
plexity to enable robust cost-effectiveness analysis, substantial
data collection may  be required [67]. When data is in short sup-
ply, theoretically informed modelling may  still be a particularly
appropriate tool to support decision-making [68,69]. Transmission
modelling using existing data explains patterns seen in average
age of infection, demonstrates the importance of carriage, suggests
optimal strategies for vaccination, and appraises the potential role
of other interventions to reduce transmissibility.
5. Conclusion
Transmission dynamics have not yet been integrated into a com-
prehensive cost-utility analysis of typhoid vaccination and, as such,
there is no economic evaluation that would meet contemporary
gold standards [9,70]. Given the costs and time involved in further
ﬁeld study, constructive efforts could be made to integrate exist-
ing transmission modelling and cost-effectiveness analyses, such
as utilising the extensive collation of typhoid epidemiological and
clinical parameters by Saul [25] with the transparent, reproducible
modelling approach of Pitzer [24], and DOMI project economic data
[30,38]. While such endeavours would not address the fundamental
limitations on health service budget in endemic areas, an analysis
of typhoid vaccination that enables economic comparison across
health arenas could help bring into the public gaze the full poten-
tial of measures to control enteric fever, and improve the prospects
of protection from typhoid for people living with daily risks from a
disease eliminated from most of the afﬂuent world.
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